Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol

Lanell M. Peterson, David A. Mankoff, Thomas Lawton, Kevin Yagle, Erin K. Schubert, Svetlana Stekhova, Allen Gown, Jeanne Link, Timothy Tewson, Kenneth Krohn

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

The PET compound 18F-fluoroestradiol (18F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r=0.99) between observers using IHC as well as the different methods of measuring ER content (P <0.001). ER-negative tumors had 18F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18F-FES PET and ER expression measured by IHC. 18F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.

Original languageEnglish (US)
Pages (from-to)367-374
Number of pages8
JournalJournal of Nuclear Medicine
Volume49
Issue number3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Immunohistochemistry
Neoplasms
Research Design
Biopsy

Keywords

  • F-FES PET
  • Breast cancer
  • Estrogen receptor
  • IHC
  • Tracer uptake

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. / Peterson, Lanell M.; Mankoff, David A.; Lawton, Thomas; Yagle, Kevin; Schubert, Erin K.; Stekhova, Svetlana; Gown, Allen; Link, Jeanne; Tewson, Timothy; Krohn, Kenneth.

In: Journal of Nuclear Medicine, Vol. 49, No. 3, 01.03.2008, p. 367-374.

Research output: Contribution to journalArticle

Peterson, LM, Mankoff, DA, Lawton, T, Yagle, K, Schubert, EK, Stekhova, S, Gown, A, Link, J, Tewson, T & Krohn, K 2008, 'Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol', Journal of Nuclear Medicine, vol. 49, no. 3, pp. 367-374. https://doi.org/10.2967/jnumed.107.047506
Peterson, Lanell M. ; Mankoff, David A. ; Lawton, Thomas ; Yagle, Kevin ; Schubert, Erin K. ; Stekhova, Svetlana ; Gown, Allen ; Link, Jeanne ; Tewson, Timothy ; Krohn, Kenneth. / Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. In: Journal of Nuclear Medicine. 2008 ; Vol. 49, No. 3. pp. 367-374.
@article{3f537577279543b6a1382bad6a514981,
title = "Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol",
abstract = "The PET compound 18F-fluoroestradiol (18F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r=0.99) between observers using IHC as well as the different methods of measuring ER content (P <0.001). ER-negative tumors had 18F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18F-FES PET and ER expression measured by IHC. 18F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.",
keywords = "F-FES PET, Breast cancer, Estrogen receptor, IHC, Tracer uptake",
author = "Peterson, {Lanell M.} and Mankoff, {David A.} and Thomas Lawton and Kevin Yagle and Schubert, {Erin K.} and Svetlana Stekhova and Allen Gown and Jeanne Link and Timothy Tewson and Kenneth Krohn",
year = "2008",
month = "3",
day = "1",
doi = "10.2967/jnumed.107.047506",
language = "English (US)",
volume = "49",
pages = "367--374",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol

AU - Peterson, Lanell M.

AU - Mankoff, David A.

AU - Lawton, Thomas

AU - Yagle, Kevin

AU - Schubert, Erin K.

AU - Stekhova, Svetlana

AU - Gown, Allen

AU - Link, Jeanne

AU - Tewson, Timothy

AU - Krohn, Kenneth

PY - 2008/3/1

Y1 - 2008/3/1

N2 - The PET compound 18F-fluoroestradiol (18F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r=0.99) between observers using IHC as well as the different methods of measuring ER content (P <0.001). ER-negative tumors had 18F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18F-FES PET and ER expression measured by IHC. 18F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.

AB - The PET compound 18F-fluoroestradiol (18F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r=0.99) between observers using IHC as well as the different methods of measuring ER content (P <0.001). ER-negative tumors had 18F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18F-FES PET and ER expression measured by IHC. 18F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.

KW - F-FES PET

KW - Breast cancer

KW - Estrogen receptor

KW - IHC

KW - Tracer uptake

UR - http://www.scopus.com/inward/record.url?scp=40449093680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449093680&partnerID=8YFLogxK

U2 - 10.2967/jnumed.107.047506

DO - 10.2967/jnumed.107.047506

M3 - Article

C2 - 18287268

AN - SCOPUS:40449093680

VL - 49

SP - 367

EP - 374

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -